Mirae Asset Global Investments Co. Ltd. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 62,569 shares of the biopharmaceutical company’s stock after buying an additional 5,403 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $35,181,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals in the second quarter worth $31,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $38,000. Berbice Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.6%

NASDAQ:REGN opened at $751.13 on Thursday. The stock has a market capitalization of $78.94 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 2.01 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $758.43 and a 200 day moving average of $647.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the company earned $12.46 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Scotiabank boosted their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 target price for the company. Finally, Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $784.77.

Insider Activity

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.